Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years or older;~* Scheduled for elective knee arthroscopy without anticipated ligamentous repair;~* Planned general anesthesia without a regional block or wound infiltration with local anesthesia;~* Planned day-of-surgery discharge.~Exclusion Criteria:~* Opioid tolerance defined by ≥15 mg of oral morphine daily or equianalgesic dose of another opioid within 30 days of surgery;~* Known hypersensitivity to sufentanil or components of DSUVIA;~* Patients with an allergy or hypersensitivity to opioids;~* Pregnancy or actively breastfeeding;~* Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug;~* Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments, including chronic pain or active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: ACTIVE_COMPARATOR): 30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
- Control Group (Type: PLACEBO_COMPARATOR): placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).